In Preparation For Its Strategic Plan Of Attracting Hundreds More Medical Practitioners And Distributors To Its Bioelectronic Devices Designed To Relieve Chronic And Acute Pain, Electromedical Technologies, Inc. (OTCQB: EMED) Has Invested $4.2 Million To Build More Than 1,200 Units, Including The FDA Cleared WellnessPro+ Device

Posted November 19, 2020

In NASDAQ: AXSM, NYSE: BMY, NYSE: BSX, NYSE: GSK, NYSE: JNJ, NYSE: LLY, NYSE: MDT, NYSE: NVRO, NYSE: NVS, NYSE: TBA, OTCQB: EMED

In Preparation For Its Strategic Plan Of Attracting Hundreds More Medical Practitioners And Distributors To Its Bioelectronic Devices Designed To Relieve Chronic And Acute Pain, Electromedical Technologies, Inc. (OTCQB: EMED) Has Invested $4.2 Million To Build More Than 1,200 Units, Including The FDA Cleared WellnessPro+ Device

Electromedical Technologies, Inc. (OTCQB: EMED) announced today (November 19, 2020) it has completed the first phase of its inventory buildup in preparation for great product demand in 2021. It has invested some $4.2 million building more than 1,200 units of its chronic and acute pain relieving, non-invasive devices. The inventory build up includes its FDA cleared WellnessPro+, which deliver bioelectronic treatments for chronic and acute pain without the use of opioid drugs. Prescription pharmaceuticals can have the harmful side effect of opioid addiction. Anticipating the on-boarding of hundreds of new medical practitioners and distributors, EMED is building up inventory of the devices as it transitions into 2021. The Company has paid in full for the inventory it built to ensure it has enough product to meet demand. In the first quarter of 2020, the Company said, it ran short of inventory to meet demand.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

EMED Offers Income Opportunity Via Its Brand Ambassador Program

Matthew Wolfson, founder and CEO of Electromedical Technologies, Inc. (OTCQB: EMED), said, “This inventory increase fits perfectly with our strategic plan of engaging and on-boarding hundreds of new medical practitioners and distributors. In today’s economic environment, many people are seeking to create new revenue streams for their families. We have a way to help thousands of people to live a better quality of life, pain free and addiction free and at the same time provide a real income opportunity for anyone who wishes to join our brand ambassador team. If interested, they can learn more here. In Preparation For Its Strategic Plan Of Attracting Hundreds More Medical Practitioners And Distributors To Its Bioelectronic Devices Designed To Relieve Chronic And Acute Pain, Electromedical Technologies, Inc. (OTCQB: EMED) Has Invested $4.2 Million To Build More Than 1,200 Units, Including The FDA Cleared WellnessPro+ device.

Bioelectronics And Electro-Modulation Relieve Chronic And Acute Pain

Wolfson added, “Every day more doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain and without having negative effects on the immune system, especially in today’s pandemic environment.” He noted that the company’s WellnessPro+ device and other non-invasive products offer pain-suffering patients bioelectronics and electro-modulation. The treatments do not require injections, invasive procedures or use of opioid pain killer pharmaceutical drugs that can have a side effect of addiction. Wolfson said the WelllnessPro device “produces real results so people can live pain free and get their lives back!” In Preparation For Its Strategic Plan Of Attracting Hundreds More Medical Practitioners And Distributors To Its Bioelectronic Devices Designed To Relieve Chronic And Acute Pain, Electromedical Technologies, Inc. (OTCQB: EMED) Has Invested $4.2 Million To Build More Than 1,200 Units, Including The FDA Cleared WellnessPro+ device.

Goldman Small Cap Research Yesterday Set A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED)

All of this inventory building for an anticipated surge in demand in 2021 comes as

Goldman Small Cap Research yesterday set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in its Opportunity Research report. The investment analysis projects that the medical device company will reach volumes of $1.55 Million in FY2021 and $17 Million in FY2022. In Preparation For Its Strategic Plan Of Attracting Hundreds More Medical Practitioners And Distributors To Its Bioelectronic Devices Designed To Relieve Chronic And Acute Pain, Electromedical Technologies, Inc. (OTCQB: EMED) Has Invested $4.2 Million To Build More Than 1,200 Units, Including The FDA Cleared WellnessPro+ device..

WelllnessPlus POD Features Portal For Remote Real-Time Monitoring Of Treatments

Succeeding in a pain prescription market estimated at $24 billion by Mizhou Securities USA, the report says the large jump in FY2022 volume it projects stems in large part from the success of the WellnessPlus POD, expected to be released in late 2021 after FDA clearance. Electromedical Technologies, Inc. (OTCQB: EMED) already markets the FDA-cleared WellnessPro Plus™ and plans to debut late next year the WellnessPlus POD, a smaller, professional, less costly device that features a portal for telemedicine-like real time monitoring by physicians. Goldman estimates that EMED may sell 80,000 devices in 2022. In Preparation For Its Strategic Plan Of Attracting Hundreds More Medical Practitioners And Distributors To Its Bioelectronic Devices Designed To Relieve Chronic And Acute Pain, Electromedical Technologies, Inc. (OTCQB: EMED) Has Invested $4.2 Million To Build More Than 1,200 Units, Including The FDA Cleared Wellness Pro+ device.

The Company has successfully marketed its non-invasive FDA-cleared WellnessPro Plus™ as an alternative treatment to opioid pain killer pharmaceuticals which can be addictive. Electromedical Technologies, Inc. (OTCQB: EMED), then, is an attractive pure play bioelectronics firm with a telemedicine component that should serve as a driver of broad product adoption, the report says. It noted that EMED’s newest product, the WellnessPro POD, links doctors and patients, and is less costly, smaller, portable, feature-intensive and offers a remote POD portal. That enables physicians real-time monitoring of treatments. It also offers a unique financial sales structure, combining down payment purchase with a prescription, plus a monthly subscription services fee.

Electromedical Technologies, Inc. (OTCQB: EMED) Stock Seen As ‘Grossly Undervalued” By Goldman Report

The Goldman report concluded: Electromedical Technologies, Inc. (OTCQB: EMED) stock is ‘grossly undervalued.’ The analysis finds, “Even with a 12-month price target of $5.70, EMED’s share are grossly undervalued.” It also asserts that its volume estimates for 2022 are based on 80,000 units sold in 2022. It notes that the stock could rise by five times its recent price over the next 12 months, it said.

Source: Stock Market Press

Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

Bina Murarka

Bina Murarka is a India-based technology reporter for Stock Market Press. A freelance writer who covered tech for various mainstream and financial websites, she writes about everything from small-cap telecommunications companies to the digital economy's impact on financial markets. She graduated from Calcutta University.